DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial

home / between-the-lines / dara-vrd-in-transplant-eligible-patients-with-newly-diagnosed-multiple-myeloma-analysis-of

Hematologic oncology specialists review recent data from the PERSEUS trial analyzing minimal residual disease in patients with newly diagnosed multiple myeloma who receive DARA-VRd.

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 1: Frontline Treatment Landscape in Transplant-Eligible Patients with NDMM

Cesar Rodriguez, MD;Frits van Rhee, MD, PhD
June 28th 2024

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD, discuss the overall frontline treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 2: Study Design of the PERSEUS Trial

Cesar Rodriguez, MD;Frits van Rhee, MD, PhD
June 28th 2024

Hematologic oncology specialists provide an overview of the study design of the PERSEUS trial and outline the role of MRD negativity in the treatment of patients with multiple myeloma.

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 3: Key Efficacy Data from PERSEUS in Newly Diagnosed Multiple Myeloma

Cesar Rodriguez, MD;Frits van Rhee, MD, PhD
July 5th 2024

Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD

EP. 4: Adverse Event Considerations for DARA-VRd in NDMM

Cesar Rodriguez, MD;Frits van Rhee, MD, PhD
July 5th 2024

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.